Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series


<jats:p>Treatment options for drug-resistant CMV are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically-confirmed resistance to letermovir while on therapy.</jats:p>






Published Version (Please cite this version)


Publication Info

Turner, Nicholas, Andrew Strand, Dilraj S Grewal, Gary Cox, Sana Arif, Arthur W Baker, Eileen K Maziarz, Jennifer H Saullo, et al. (n.d.). Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series. Antimicrobial Agents and Chemotherapy. 10.1128/aac.02337-18 Retrieved from

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.